Abbott Laboratories — Jul 16, 2026 release

As a result, $55 million of sales in the second quarter of 2025 and $101 million of sales in the first half of 2025 were moved from Structural Heart to Electrophysiology. Refer to pages 16 and 17 for a reconciliation of comparable sales growth. Page 6 of 21 Abbott's Financial Guidance Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5% 1 . Abbott projects full-year 2026 adjusted diluted earnings per share of $5.45 to $5.60. Abbott projects third-quarter 2026 adjusted diluted earnings per share of $1.38 to $1.46 . Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP. Abbott Declares 410 th Consecutive Quarterly Dividend On June 12, 2026, the board of directors of Abbott declared the company's quarterly dividend of $0.63 per share. Abbott's cash dividend is payable Aug. 17, 2026, to shareholders of record at the close of business on July 15, 2026. Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. Abou